GaBI Journal-Generics and Biosimilars Initiative Journal
Scope & Guideline
Empowering Research in Generics and Biosimilars
Introduction
Aims and Scopes
- Biosimilars Development and Approval Processes:
The journal extensively covers the methodologies and regulatory frameworks for the development and approval of biosimilars, emphasizing the need for rigorous standards in clinical trials and post-market surveillance. - Economic and Policy Implications:
Research published in the journal often explores the economic aspects of biosimilars and generics, including pricing strategies, market access, and the impact of healthcare policies on patient access to these medications. - Pharmacokinetics and Bioequivalence Studies:
A significant focus is placed on pharmacokinetic studies and bioequivalence evaluations, providing insights into clinical research methodologies that ensure the safety and efficacy of biosimilars compared to their reference products. - Public Perception and Acceptance:
The journal examines the attitudes and perceptions of healthcare professionals and patients towards biosimilars, highlighting factors that influence their acceptance and usage in clinical practice. - Global Perspectives on Biosimilars:
Research articles often present a global view on biosimilars, discussing market trends, regulatory challenges, and successful case studies from various countries.
Trending and Emerging
- Healthcare Policy and Drug Pricing:
Recent publications are increasingly addressing the impact of healthcare policies, such as drug price negotiations, on patient access to medications, highlighting the relevance of economic factors in the biosimilars market. - Ethnic Sensitivity and Clinical Development:
There is a growing emphasis on assessing ethnic sensitivity in clinical trials for biosimilars, which is crucial for ensuring that these products are safe and effective across diverse populations. - Pharmacovigilance and Post-Market Studies:
The focus on pharmacovigilance and long-term post-market studies is increasing, reflecting a demand for robust safety data and monitoring as biosimilars gain market share. - Interchangeability and Substitution Policies:
A trend towards more nuanced discussions around interchangeability, substitution policies, and the implications of switching between biosimilars and their reference products is emerging. - Innovations in Manufacturing and Quality Control:
There is a rising interest in innovative manufacturing processes and quality control measures for biosimilars, indicating a shift towards ensuring product integrity and reliability.
Declining or Waning
- Traditional Generic Drug Development:
There has been a noticeable decline in articles specifically focused on traditional generic drug development, as the journal shifts its attention more towards biosimilars and their unique challenges. - Static Regulatory Frameworks:
Research discussing established regulatory frameworks without innovative updates or challenges has decreased, reflecting a transition towards more dynamic discussions on evolving regulations in the biosimilar space. - Single-Country Case Studies:
Publications that focus solely on case studies from individual countries have become less frequent, as the journal increasingly emphasizes comparative studies and global perspectives. - Historical Analysis of Drug Markets:
Fewer articles are dedicated to historical analyses of drug markets, indicating a shift towards more current and forward-looking discussions regarding biosimilars and generics.
Similar Journals
Clinical Pharmacology in Drug Development
Empowering professionals with cutting-edge pharmacological insights.Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Fostering knowledge in pharmacology for real-world impact.JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.
Journal of Pioneering Medical Sciences
Exploring new frontiers in medical science and practice.Journal of Pioneering Medical Sciences, published by JPMS PUBL in Karachi, Pakistan, stands as a vital resource in the field of medical research and practice. Established in 2012, this Open Access journal fosters the dissemination of innovative findings and groundbreaking studies that contribute to the advancement of medical science. With an ISSN of 2309-7981 and a commitment to rigorous peer-review, the journal encompasses a diverse range of topics, aiming to bridge knowledge gaps and promote interdisciplinary dialogue among healthcare professionals and researchers. Although it currently lacks an H-index, its focus on pioneering medical studies positions it as a platform for impactful contributions that can shape future healthcare policies and practices. The journal's open access policy ensures that vital research is freely available to a global audience, promoting accessibility and collaboration in the medical community.
Universitas Medica
Fostering collaboration in the pursuit of medical excellence.Universitas Medica is a prominent journal dedicated to advancing the field of medical sciences, published by the Pontificia Universidad Javeriana, Facultad de Medicina. Since its transition to an Open Access format in 2010, it has played a pivotal role in promoting the dissemination of high-quality medical research. Featuring a diverse array of studies encompassing clinical practice, public health, and medical education, Universitas Medica aims to provide researchers, healthcare professionals, and students with invaluable insights and the latest findings in medicine. With a focus on enhancing accessibility and fostering collaboration across the medical community, this journal stands out as a critical resource for those looking to stay abreast of innovations and trends. The journal is indexed under ISSN 0041-9095 and E-ISSN 2011-0839 and operates from its base in Bogotá, Colombia, contributing significantly to the scientific landscape both regionally and internationally.
Journal of Taibah University Medical Sciences
Exploring the Frontiers of Medical Science TogetherWelcome to the Journal of Taibah University Medical Sciences, a distinguished open-access publication dedicated to advancing knowledge in the field of medicine. Since its inception in 2006, and published by ELSEVIER, this journal has become a vital resource for researchers and healthcare professionals alike, reflecting a steadfast commitment to disseminating innovative research and high-quality medical studies. With an impressive impact factor and a Scopus ranking placing it in the top 25% of general medicine journals, this publication occupies a notable position in the academic landscape. The journal covers a wide array of topics within the medical sciences, from clinical research to public health initiatives. As a Q3 category journal in the 2023 rankings, it continues to attract submissions that contribute meaningfully to the diverse and evolving field of medicine, supporting an open-access model that ensures widespread accessibility to its invaluable content. Explore the Journal of Taibah University Medical Sciences to stay abreast of the latest scientific advancements and engage with fellow scholars across the globe.
International Journal of Clinical Pharmacy
Empowering Healthcare through Innovative Pharmaceutical ResearchThe International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.
THERAPEUTIC DRUG MONITORING
Driving Excellence in Personalized Pharmaceutical CareTHERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.
DRUGS
Unveiling Breakthroughs in Drug DevelopmentDRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.
Nobel Medicus
Connecting Researchers to Transform Healthcare Insights.Nobel Medicus, published by NOBEL ILAC, is a Turkish academic journal that has been contributing to the field of medicine since its inception in 2005. With an ISSN of 1305-2381, this journal focuses on a broad spectrum of medical research, catering to both clinical and academic professionals. Although currently positioned in the Q4 quartile for miscellaneous medicine according to 2023 category rankings, the journal aims to promote innovative and impactful studies, providing a platform for promising research within a competitive landscape. The journal's commitment to accessibility for the global research community is critical, even in the absence of open access options. Placed in the 7th percentile with a Scopus rank of #586 out of 636 in the general medicine category, it seeks to grow in influence and visibility. As such, Nobel Medicus plays an important role in disseminating valuable medical insights, fostering connections among researchers, healthcare professionals, and emerging scholars in the field.
CURRENT MEDICAL RESEARCH AND OPINION
Transforming Opinions into Evidence-Based Practices.CURRENT MEDICAL RESEARCH AND OPINION, published by Taylor & Francis Ltd, is a distinguished journal that has been at the forefront of medical research since its inception in 1972. With a vested interest in advancing healthcare knowledge, this journal encompasses a wide array of disciplines within the medical field, categorizing itself in Q2 of the Medicine (Miscellaneous) category according to the 2023 rankings. Notably, it holds a commendable rank of #119 out of 636 in the General Medicine category on Scopus, indicating its relevance and influence within the medical community, supported by an 81st percentile ranking. Although it does not present Open Access options, the comprehensive research articles, systematic reviews, and expert opinions it publishes are crucial for researchers, clinicians, and students who seek to deepen their understanding and drive innovations in medical practice. With its commitment to high-quality and impactful scientific communication, CURRENT MEDICAL RESEARCH AND OPINION remains an essential resource for those dedicated to advancing healthcare and improving patient outcomes.